GlassScriptPhysician profile
Glenn T Young
NPI 1518046341
$4,952.59
in general payments reported to CMS, 2019-2025
31 companies · $49.00 in 2025
The $49.00 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $326 · 2021: $852 · 2022: $981 · 2023: $1,314 · 2024: $1,043 · 2025: $49.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,851.92 | 2019-2024 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $598.87 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $223.24 | 2019-2024 | Stelara, Simponi Aria, Simponi |
| Ardelyx, INC. | $195.87 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $182.04 | 2019-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $176.87 | 2022-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $146.34 | 2019-2024 | Ocaliva |
| Genzyme Corporation | $141.96 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.16 | 2019-2024 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $109.41 | 2024 | |
| Gilead Sciences, INC. | $109.41 | 2024 | Vemlidy |
| Celgene Corporation | $105.17 | 2021-2023 | Zeposia |
| Axonics, INC. | $95.29 | 2021-2023 | Axonics |
| Nestle Healthcare Nutrition INC. | $93.68 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $92.04 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $86.33 | 2024-2025 | Pillcam, Gi Genius |
| Vivus LLC | $82.57 | 2021-2023 | Qsymia |
| Evoke Pharma, INC. | $82.55 | 2021-2024 | Gimoti |
| Phathom Pharmaceuticals, INC. | $69.46 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $69.23 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $49.07 | 2019-2023 | Linzess |
| Allergan, INC. | $48.55 | 2019-2020 | |
| Braintree Laboratories, INC. | $46.87 | 2019-2024 | Suflave |
| Ferring Pharmaceuticals INC. | $30.76 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $25.94 | 2024 | Rapide Balloons |
| Cumberland Pharmaceuticals, INC. | $24.72 | 2019 | |
| Myriad Genetic Laboratories, INC. | $24.00 | 2023 | Precisetumor |
| Lilly USA, LLC | $22.88 | 2024 | Omvoh |
| Ethicon US, LLC | $20.45 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.23 | 2021 | |
| Redhill Biopharma INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.